{
  "relevance_rule": {
    "rule_text": "All abstracts that have client provided keywords",
    "approach": "keywords",
    "key_concepts": {
      "keywords": [
        "Hyperphosphatemia",
        "Parathyroid hormone",
        "Calcitriol",
        "Chronic kidney disease",
        "ESRD",
        "Phosphate binder",
        "Sevelamer",
        "sucroferric oxyhydroxide",
        "lanthanum carbonate",
        "Ferric citrate",
        "Calcium acetate",
        "Constipation",
        "Tenapanor",
        "Claudins",
        "FGF receptor",
        "Albuminuria",
        "nicotinamide",
        "vitamin D",
        "SGLT2 inhibitors",
        "canagliflozin",
        "Dapagliflozin",
        "Empagliflozin",
        "Ozempic",
        "Calcium carbonate",
        "Serum phosphate",
        "Phosphate",
        "Fibroblast growth factor 23",
        "Hemodialysis",
        "Dialysis",
        "Dialysis Outcomes and Practice Patterns Study",
        "Sodium hydrogen transport exchanger 3",
        "sodium-dependent phosphate cotransporter 2b",
        "KDIGO",
        "KDOQI",
        "Sodium",
        "Phosphorus",
        "Klotho",
        "Tight junctions",
        "Occludins",
        "Vascular calcification",
        "Bristol Stool Form Scale",
        "Interdialytic weight gain",
        "peritoneal dialysis",
        "NTX1942",
        "SLC34A2",
        "Glomerular",
        "CKD-MBD",
        "Smooth muscle calcification",
        "Oxylanthanum carbonate"
      ],
      "categories": [],
      "contextual_concepts": []
    },
    "reasoning": "Explicitly stated as the relevance rule and matches the guideline for relevance filtering using client keywords."
  },
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Phase 2 data, Phase 3 data (including meta-analyses), real-world data (including PROs and registry data), Phosphate binders/phosphate lowering treatment; EXCLUDES Ardelyx sponsored abstracts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 2",
          "Phase II",
          "Phase 3",
          "Phase III",
          "meta-analysis",
          "real-world data",
          "PROs",
          "patient reported outcomes",
          "registry data",
          "Phosphate binder",
          "phosphate lowering treatment"
        ],
        "categories": [
          "Clinical trial phase",
          "Real-world evidence",
          "Treatment type"
        ],
        "contextual_concepts": [
          "Meta-analyses",
          "Patient reported outcomes",
          "Registry data"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored"
      ],
      "reasoning": "Requires both keyword and context matching for phases, real-world data, and specific treatment types. Excludes Ardelyx sponsored abstracts to ensure mutual exclusivity with Internal priority."
    },
    {
      "priority": "Internal",
      "rule_text": "Ardelyx sponsored abstracts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ardelyx sponsored",
          "Ardelyx"
        ],
        "categories": [
          "Sponsor"
        ],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "Can be identified by keyword matching for sponsorship; mutually exclusive from other priorities."
    },
    {
      "priority": "Medium",
      "rule_text": "Phase 1 data, retrospective analyses, prognostic studies, trial designs, preclinical studies; studies with trial outcomes and endpoints; other general studies; EXCLUDES Ardelyx sponsored abstracts and all High priority concepts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 1",
          "Phase I",
          "retrospective analysis",
          "prognostic study",
          "trial design",
          "preclinical study",
          "trial outcomes",
          "endpoints"
        ],
        "categories": [
          "Clinical trial phase",
          "Study type",
          "Outcomes"
        ],
        "contextual_concepts": [
          "General studies",
          "Trial outcomes",
          "Endpoints"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "real-world data",
        "PROs",
        "patient reported outcomes",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment"
      ],
      "reasoning": "Requires both keyword and context matching for study types and outcomes, and excludes Ardelyx sponsored and High priority concepts for mutual exclusivity."
    },
    {
      "priority": "Low",
      "rule_text": "All abstracts that only have mention of an indication and does not include any other data; EXCLUDES Ardelyx sponsored abstracts and all higher priority concepts",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [
          "Indication only"
        ],
        "contextual_concepts": [
          "Mention of indication without data",
          "No study data",
          "No outcomes",
          "No endpoints"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 1",
        "Phase I",
        "Phase 2",
        "Phase II",
        "Phase 3",
        "Phase III",
        "meta-analysis",
        "real-world data",
        "PROs",
        "patient reported outcomes",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment",
        "retrospective analysis",
        "prognostic study",
        "trial design",
        "preclinical study",
        "trial outcomes",
        "endpoints"
      ],
      "reasoning": "Requires semantic/contextual analysis to determine if only indication is mentioned without any data, and excludes all higher priority concepts for mutual exclusivity."
    }
  ]
}